2023-08-30-ITIF-保持美国生物制药的领导地位_为什么小型_研究密集型公司在美国创新生态系统中很重要（英）_17页_637kb

Preserving US Biopharma Leadership: Why Small, Research-Intensive Firms Matter

Small, research-intensive (SRI) biopharma firms are critical to U.S. competitiveness and drug development. The U.S. leads in this sector, hosting 85% of global SRI biopharma firms (193 out of 260 globally). These firms contribute significantly to R&D, accounting for 18% of U.S. biopharma R&D spending, with an average spend per employee of $712,258—nearly eight times higher than larger firms.

SRI biopharma firms face challenges, especially in the drug development “valley of death” phase. However, they play a disproportionate role in innovation, with U.S. SRI firms driving significant downstream R&D productivity. The U.S. innovation ecosystem, supported by venture capital, university partnerships, and policies like the Bayh-Dole Act, fosters this environment.

Key policy recommendations include:

• Passing the American Innovation and Jobs Act to enhance R&D tax credits and restore immediate expensing.
• Repealing Section 174 of the tax code to allow full expensing of R&D costs.
• Amending Section 382 to retain net operating losses and credits even with ownership changes.

Congress must act to support SRI biopharma firms, bridge the funding gap, and maintain U.S. leadership in biopharma innovation.

Key Data:

• 193 U.S. SRI biopharma firms (85% global total).
• SRI biopharma firms in U.S. spend $637,735 per employee on R&D.
• U.S. SRI biopharma firms spend nearly twice as much per employee as global counterparts.